CSF3 and liver disorder: Similarly, the GRAFT trial, a European multicenter randomized study, failed to demonstrate a significant survival benefit of G-CSF compared to standard of care in patients with ACLF, of whom 55% in the G-CSF group had alcohol-associated liver disease [86].